Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses FDA’s approval of Axi-Cel and 42% of patients have long-term durability at the 2017 American Society of Hematology.
FDA Approval of Axi-Cel – 42% of patients have long-term durability
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses FDA’s approval of Axi-Cel and 42% of patients have long-term durability at the 2017 American Society of Hematology.